1-20 of 35
Tibor Keler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Mark H O'Hara, Max Wattenberg, Ignacio Garrido-Laguna, Eileen M O'Reilly, Michael Yellin, Tibor Keler, Michele Gargano, Nick Niles, Jeremy Drees, Nandita Bose, Gregory L Beatty
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): B061.
https://doi.org/10.1158/1538-7445.PANCREATIC24-B061
Published: 15 September 2024
View article titled, Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy
Journal Articles

Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Mark H O'Hara, Max Wattenberg, Ignacio Garrido-Laguna, Eileen M O'Reilly, Michael Yellin, Tibor Keler, Michele Gargano, Nick Niles, Jeremy Drees, Nandita Bose, Gregory L Beatty
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): PR-10.
https://doi.org/10.1158/1538-7445.PANCREATIC24-PR-10
Published: 15 September 2024
View article titled, Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy
Journal Articles

Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells

Bin-Jin Hwang, Erika Crosby, Timothy Trotter, Li-Chung Tsao, Tao Wang, Congxiao Liu, Xiao Yang, Gangjun Lei, Junping Wei, Xingru Ma, Bushanqing Liu, Amy Hobeika, Michael Morse, Tibor Keler, Li-Zhen He, Herbert Kim Lyerly, Zachary Hartman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5296.
https://doi.org/10.1158/1538-7445.AM2024-5296
Published: 22 March 2024
View article titled, Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells
Journal Articles

Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4

Lawrence J. Thomas, Laura A. Vitale, Michael Murphy, Collin Xia, Zeyu Peng, Asma Ejas, Montu Patel, James Boyer, April R. Baronas, Thomas O'Neill, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Mark Ma, Mingjiu Chen, Hugh M. Davis, Russ A. Hammond, Cherie Taglienti, Michael Yellin, Joel Goldstein, Diego Alvarado, Henry C. Marsh, Tibor Keler
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2963.
https://doi.org/10.1158/1538-7445.AM2023-2963
Published: 04 April 2023
View article titled, Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4
Journal Articles

Abstract 1865: Simultaneous de-repression of innate and adaptive immune responses through dual targeting of ILT4 and PD(L)-1 with bispecific antibodies

Laura Vitale, Mike Murphy, Jeff Weidlick, Anna Wasiuk, Thomas O'Neill, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Colleen Patterson, James Boyer, Linda Crew, Edward J. Natoli, Jay S. Lillquist, Joel Goldstein, Lawrence J. Thomas, Henry C. Marsh, Diego Alvarado, Tibor Keler
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1865.
https://doi.org/10.1158/1538-7445.AM2021-1865
Published: 01 July 2021
View article titled, Abstract 1865: Simultaneous de-repression of innate and adaptive immune responses through dual targeting of ILT4 and PD(L)-1 with bispecific antibodies
Journal Articles

Abstract P5-04-03: Conversion of non-T cell-inflamed triple-negative breast cancer by in situ immunomodulation of induced intratumoral cross-presenting dendritic cells

Takaaki Oba, Tibor Keler, Henry C Marsh, Scott Abrams, Fumito Ito
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-04-03.
https://doi.org/10.1158/1538-7445.SABCS19-P5-04-03
Published: 15 February 2020
View article titled, Abstract P5-04-03: Conversion of non-T cell-inflamed triple-negative breast cancer by <em>in situ</em> immunomodulation of induced intratumoral cross-presenting dendritic cells
Journal Articles

Abstract 2392: CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1

Laura A. Vitale, Lawrence J. Thomas, Thomas O'Neill, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Colleen Patterson, Anna Wasiuk, Eric Forsberg, James Boyer, Crystal Sisson, Jeffrey Weidlick, Shannon Renn-Bingham, Ioannis Papayannopoulos, Russ Hammond, Joel Goldstein, Henry C. Marsh, Tibor Keler, Li-Zhen He
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2392.
https://doi.org/10.1158/1538-7445.AM2019-2392
Published: 01 July 2019
View article titled, Abstract 2392: CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1
Journal Articles

Abstract 1555: Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases

Diego Alvarado, Laura Vitale, Mike Murphy, Thomas O'Neill, Andrew Proffitt, Jay Lillquist, Gwenda Ligon, Komal Patel, Anna Wasiuk, Jeff Weidlick, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Colleen Patterson, Russell A. Hammond, Li-Zhen He, Joel Goldstein, Lawrence J. Thomas, Henry C. Marsh, Tibor Keler, Richard Gedrich
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1555.
https://doi.org/10.1158/1538-7445.AM2019-1555
Published: 01 July 2019
View article titled, Abstract 1555: Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases
Journal Articles

Abstract 3217: Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA

Lawrence J. Thomas, Li-Zhen He, Lauren E. Gergel, Eric M. Forsberg, Elizabeth Q. Do, James M. Boyer, April R. Baronas, Mallary Rocheleau, Kathleen M. Borrelli, Anna Wasiuk, Jeffrey Weidlick, Henry C. Marsh, Bart R. Anderson, SubbaRao Nallagatla, Richard Kang, Ekambar R. Kandimalla, Tibor Keler
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3217.
https://doi.org/10.1158/1538-7445.AM2019-3217
Published: 01 July 2019
View article titled, Abstract 3217: Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA
Journal Articles

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

Rachel E. Sanborn, Nashat Y. Gabrail, Nina Bhardwaj, Michael S. Gordon, Mark O'Hara, Danny Khalil, Thomas Hawthorne, Richard Gedrich, Laura Vitale, Mark Rogalski, Tianshu Li, Tracey Rawls, Tibor Keler, Michael Yellin
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-194.
https://doi.org/10.1158/1538-7445.AM2019-LB-194
Published: 01 July 2019
View article titled, Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Journal Articles

Abstract CT005: FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer

Nitin Ohri, Balazs Halmos, Haiying Cheng, Tony Abraham, Tahir Yahya, Madhur Garg, William Bodner, Rafi Kabarriti, Shalom Kalnicki, Michael J. Yellin, Tibor Keler, Chandan Guha
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT005.
https://doi.org/10.1158/1538-7445.AM2018-CT005
Published: 01 July 2018
View article titled, Abstract CT005: FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer
Journal Articles

Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models

Lawrence J. Thomas, Li-Zhen He, James Testa, Anna Wasiuk, Jeffrey Weidlick, Crystal Sisson, Laura A. Vitale, Thomas O'Neill, Eric Forsberg, Catherine D. Pilsmaker, Lauren E. Gergel, Elizabeth Q. Do, James Boyer, April R. Baronas, Mallary Rocheleau, Michelle E. Grealish, Kathleen M. Borrelli, Henry C. Marsh, Tibor Keler
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3816.
https://doi.org/10.1158/1538-7445.AM2018-3816
Published: 01 July 2018
View article titled, Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models
Journal Articles

Abstract 5624: Development of novel bispecific immune modulating antibodies

Laura A. Vitale, Lawrence J. Thomas, Li-Zhen He, Thomas O'Neill, Jenifer Widger, Andrea Crocker, James Testa, Karuna Sundarapandiyan, Eric Forsberg, James Boyer, James Storey, Joel Goldstein, Henry C. Marsh, Tibor Keler
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5624.
https://doi.org/10.1158/1538-7445.AM2018-5624
Published: 01 July 2018
View article titled, Abstract 5624: Development of novel bispecific immune modulating antibodies
Journal Articles

Abstract 3664: CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors

Li-Zhen He, Jenifer Widger, James Testa, Laura Mills-Chen, Biwei Zhao, Jeff Weidlick, Crystal Sisson, Anna Wasiuk, Laura Vitale, Joel Goldstein, Henry Marsh, Tibor Keler, Venky Ramakrishna
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3664.
https://doi.org/10.1158/1538-7445.AM2017-3664
Published: 01 July 2017
View article titled, Abstract 3664: CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors
Journal Articles

Abstract 1373: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues

Abdel Halim, Rebecca G. Bagley, Lisa Dauffenbach, Eric P. Olsen, Tibor Keler
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1373.
https://doi.org/10.1158/1538-7445.AM2016-1373
Published: 15 July 2016
View article titled, Abstract 1373: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues
Journal Articles

Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

Rachel E. Sanborn, Michael J. Pishvain, Margaret K. Callahan, Naiyer Rizvi, Harriet Kluger, Michael Yellin, Tracey Rawls, Laura Vitale, Abdel Halim, Tom Davis, Tibor Keler
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT023.
https://doi.org/10.1158/1538-7445.AM2016-CT023
Published: 15 July 2016
View article titled, Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Journal Articles

Abstract LB-081: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy

Thomas U. Marron, Nina Bhardwaj, Linda Hammerich, Seunghee Kim-Schulze, Tibor Keler, Tom Davis, Elizabeth Crowley, Andres M. Salazar, Joshua Brody
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-081.
https://doi.org/10.1158/1538-7445.AM2016-LB-081
Published: 15 July 2016
View article titled, Abstract LB-081: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy
Journal Articles

Abstract 4866: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy

Laura A. Vitale, Thomas O’Neill, Jenifer Widger, Andrea Crocker, Li-Zhen He, Jeffrey Weidlick, Karuna Sundarapandiyan, James Storey, Lawrence Thomas, Joel Goldstein, Henry C. Marsh, Tibor Keler
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4866.
https://doi.org/10.1158/1538-7445.AM2016-4866
Published: 15 July 2016
View article titled, Abstract 4866: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy
Journal Articles

Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma

Abdel Halim, Rebecca G. Bagley, Tibor Keler
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 5032.
https://doi.org/10.1158/1538-7445.AM2016-5032
Published: 15 July 2016
View article titled, Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma
Journal Articles

Abstract 4209: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer

Bernadette V. Marquez, Supum Lee, Tibor Keler, Thomas Hawthorne, Jeremy Hoog, Shunqiang Li, Cynthia Ma, Suzanne E. Lapi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4209.
https://doi.org/10.1158/1538-7445.AM2016-4209
Published: 15 July 2016
View article titled, Abstract 4209: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer